AIDS 2024 | WHO-Recommended Triple HIV Testing Algorithm Significantly Improves Diagnostic Accuracy

AIDS 2024 | WHO-Recommended Triple HIV Testing Algorithm Significantly Improves Diagnostic Accuracy

In 2023, the World Health Organization (WHO) recommended that countries with low HIV prevalence adopt a triple testing approach to confirm HIV-positive diagnoses. Specifically, WHO advises countries with an HIV prevalence below 5% to use three consecutive tests to ensure a 99% diagnostic accuracy. The proportion of positive HIV tests in a population can impact diagnostic accuracy, and when the HIV positivity rate is below 5%, at least three consecutive tests are required to guarantee a 99% accuracy rate in diagnosis.
AIDS Dialogue | Acute HIV Infection Detection: A Critical Battle to Block Transmission and Improve Prognosis

AIDS Dialogue | Acute HIV Infection Detection: A Critical Battle to Block Transmission and Improve Prognosis

Early detection and treatment of HIV play a crucial role in AIDS prevention and control. A critical battlefield is emerging with increasing importance—the timely detection of acute HIV infection (AHI). AHI refers to the period from the entry of the HIV virus into the body until antibodies become detectable, typically occurring within a few weeks to a few months after infection. During this period, the virus replicates rapidly within the body, leading to a sharp increase in viral load, reaching its peak concentration. Consequently, individuals with AHI are at high risk of transmitting HIV and are a key focus for controlling the spread of the virus. At the 25th International AIDS Conference (AIDS2024), Infectious Diseases Frontier(IIDF) invited Dr. Eduard Sanders from the Aurum Institute in Johannesburg, South Africa, and Dr. Hugo Xi, Senior Medical Director of Scientific and Clinical Affairs at Abbott, to discuss the strategic importance and urgency of AHI detection. They emphasized the immense potential of innovative fourth-generation rapid HIV screening tests in identifying highly infectious individuals. Faced with challenges such as high testing costs, limited data, and false positives, they call for increased public awareness of AHI and advocate for policy adjustments and technological advancements to ensure more people benefit from this crucial testing.
AIDS Interview | High-Risk Factors and Strategies for HIV Vertical Transmission

AIDS Interview | High-Risk Factors and Strategies for HIV Vertical Transmission

On the global journey to eliminate HIV infections among children, different countries and regions face distinctly different challenges. Recently, at the AIDS2024 conference, Dr. Kira Elsbernd from the University of Munich in Germany delivered a special report on the risk factors involved in HIV vertical transmission and was interviewed by Infectious Diseases Frontier(IIDF). Dr. Elsbernd pointed out that there are significant differences in the rates of HIV vertical transmission between Mozambique and Tanzania. Key factors such as age, duration of antiretroviral therapy, number of antenatal care visits, and viral load at the time of delivery play crucial roles. To effectively reduce the mother-to-child transmission rate of HIV, she emphasized the need for a deep understanding of these risk factors and the design of targeted interventions. Additionally, Dr. Elsbernd expressed optimism about emerging fields and technologies, such as point-of-care diagnostics and broadly neutralizing antibodies, which she believes will play a significant role in the future prevention of pediatric HIV.
AIDS Exclusive Interview | Caring for Children with HIV: Advances in Pediatric HIV Care

AIDS Exclusive Interview | Caring for Children with HIV: Advances in Pediatric HIV Care

Pediatric care and treatment for children with HIV infection have always been a critical component in the global fight against AIDS. Recently, at the AIDS2024 conference, Dr. Anna Turkova from University College London shared her insights with Infectious Diseases Frontier(IIDF) on the breakthrough advancements in pediatric HIV care. She highlighted that the detection and diagnosis of undiagnosed children with HIV remain a major challenge that requires ongoing effort and investment. While the use of dolutegravir-based triple oral therapy has led to significant success in treating pediatric HIV, the development and application of innovative therapies such as long-acting injectables are still in progress. Additionally, psychosocial support is crucial in pediatric HIV care. Looking to the future, Dr. Turkova envisions long-acting injectable preventive treatments, painting a hopeful picture for the global pediatric HIV care landscape.
Dr. Rumi: Analysis of Effective Intervention Methods for MAFLD and HCC

Dr. Rumi: Analysis of Effective Intervention Methods for MAFLD and HCC

Recently, Combined GIHep&SHC 2024 was successfully held in Singapore. Experts in the field of liver disease from around the world gathered together to discuss the latest developments, challenges, and opportunities in liver disease. Reporters from Hepatology Digest rushed to the scene and conducted interviews with multiple experts. During the interview, Dr. Md Shofequnnabi Rumi, Assistant Professor at Enam Medical College Affiliated Hospital in Bangladesh, discussed the current status of treatment for viral hepatitis, metabolic associated fatty liver disease (MAFLD), hepatocellular carcinoma (HCC), and other related topics.
Type 2 Diabetes as a Significant Factor Increasing Mortality After Liver Transplantation

Type 2 Diabetes as a Significant Factor Increasing Mortality After Liver Transplantation

At the recently concluded American Diabetes Association (ADA) Annual Meeting, an oral presentation highlighted that liver transplant patients with type 2 diabetes (T2DM) have significantly higher postoperative mortality rates compared to those without diabetes. This finding holds substantial importance for improving liver transplant success rates and enhancing long-term survival outcomes for patients.
Dr. Daniel Huang Qingyao: Exploring the Challenges and Future Trends of Fatty Liver in Asia

Dr. Daniel Huang Qingyao: Exploring the Challenges and Future Trends of Fatty Liver in Asia

he Combined GlHep&SHC 2024 Conference will be held in Singapore from July 25th to 28th, 2024. Dr. Daniel Huang Qingyao from the National University Hospital of Singapore gave multiple presentations at the meeting. Hepatology Digest invited Dr. Daniel Huang Qingyao to share on metabolic associated fatty liver disease (MAFLD), liver disease examination methods, and other related topics. The following is an interview transcript.
2024 CUDA丨Dr. Hao Zeng: Optimizing Treatment Strategies for Advanced Renal Cell Carcinoma, Exploring New Possibilities for Greater Patient Benefit

2024 CUDA丨Dr. Hao Zeng: Optimizing Treatment Strategies for Advanced Renal Cell Carcinoma, Exploring New Possibilities for Greater Patient Benefit

In recent years, with the advancements in targeted therapy and immunotherapy, significant progress has been made in the treatment of advanced renal cell carcinoma (RCC). Several large-scale phase III clinical trials involving targeted and immunotherapy combinations have been successful, marking the beginning of a new era in first-line treatment for advanced RCC. Following the successful 2024 Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association in Xi'an, Urology Frontier invited Dr. Hao Zeng from West China Hospital, Sichuan University, to share insights on unmet needs in advanced RCC, strategies for combining targeted and immunotherapy, management of adverse events, and future directions in treatment.
2024 CUDA丨Dr. Liqun Zhou: Spotlight on Innovation, Domestic Surgical Robots at the Global Forefront

2024 CUDA丨Dr. Liqun Zhou: Spotlight on Innovation, Domestic Surgical Robots at the Global Forefront

From August 8th to 11th, 2024, the Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association (CUDA) was held in Xi'an. The conference, organized by the Chinese Medical Doctor Association and the Urology Physicians Branch, and hosted by Xijing Hospital of the Air Force Medical University, with support from the Urology Physicians Branch of the Shaanxi Medical Doctor Association, showcased the latest achievements in urology from a broad and diverse perspective under the theme "Healthy China, Urology Leads the Way." On the first day of academic sessions (August 9th), Urology Frontier interviewed the honorary chairman of the conference, Dr. Liqun Zhou of Peking University First Hospital, who shared insights on the highlights of the conference, the current status of surgical robot development in urology, and provided guidance for the development of multidisciplinary team (MDT) treatment in grassroots hospitals.
2024 CUDA | Dr. Jianming Guo: Addressing Clinical Needs of Prostate Cancer in China – Exploring Treatment Prospects from Diagnosis to Surgery

2024 CUDA | Dr. Jianming Guo: Addressing Clinical Needs of Prostate Cancer in China – Exploring Treatment Prospects from Diagnosis to Surgery

From August 8-11, 2024, the Annual Meeting of the Chinese Urological Association (CUDA) was held in Xi'an, hosted by the Chinese Medical Doctor Association and its Urological Physician Branch, organized by Xijing Hospital of the Air Force Medical University, and co-hosted by the Urology Physician Branch of the Shaanxi Medical Doctor Association. Under the theme "Healthy China, Urology First," the conference showcased the latest advancements in urology from a broad perspective and multiple dimensions. On the first day of the academic sessions (August 9), Urology Frontier interviewed the conference host, Dr. Jianming Guo from Zhongshan Hospital affiliated with Fudan University, to share insights on the unmet clinical needs of prostate cancer in China, recent breakthroughs in clinical research, and future exploration directions.